Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fixed dose combination Ciprofloxacin/Celecoxib · 2 trials · 3 indications
Treatment emergent adverse event is any medical event associated with the drug
Number of patients whose treatment is stopped prematurely for any reason
Number of patients whose treatment is stopped prematurely specifically due to adverse events
| Arm | Type | Description |
|---|---|---|
| Fixed dose Ciprofloxacin and Celecoxib | EXPERIMENTAL | Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day |
| Name | Type | Description |
|---|---|---|
| Fixed dose combination Ciprofloxacin/Celecoxib | DRUG | Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day |
Inclusion Criteria: 1. Able to comprehend and willing to sign an Informed Consent Form (ICF) 2. Males or females between the ages of 18 and 75 years of age, inclusive 3. Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for a...
The fixed dose combination Ciprofloxacin/Celecoxib is being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. It is an investigational small molecule combination therapy intended to address this neurological condition.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is developing the fixed dose combination of Ciprofloxacin and Celecoxib for ALS. The company is conducting clinical trials to evaluate this combination therapy in patients with the disease.
The fixed dose combination Ciprofloxacin/Celecoxib is in clinical development, with completed Phase 1 and Phase 2 trials for ALS. It remains investigational and has not been approved by regulatory authorities.
Two clinical trials have been completed for this combination in ALS: NCT04090684, a Phase 1 study in the United States with 10 participants, and NCT04165850, a Phase 2 open-label study in Israel with 16 participants. Both enrolled adults aged 18 and older.
No, the fixed dose combination Ciprofloxacin/Celecoxib is a specific combination of the two drugs, Ciprofloxacin and Celecoxib, formulated together as a single therapy for ALS. It is distinct from using either drug alone.